24.12.2014 Views

Guidelines for the Early Clinical and Public Health Management of ...

Guidelines for the Early Clinical and Public Health Management of ...

Guidelines for the Early Clinical and Public Health Management of ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>Guidelines</strong> <strong>for</strong> <strong>the</strong> <strong>Early</strong> <strong>Clinical</strong> <strong>and</strong> <strong>Public</strong> <strong>Health</strong> <strong>Management</strong> <strong>of</strong> Bacterial Meningitis (including Meningococcal Disease)<br />

7.6.4 Cases <strong>of</strong> confirmed serogroup A, W 135<br />

or Y infections<br />

• Index cases who have not been immunised with <strong>the</strong> conjugate quadrivalent (ACW 135<br />

Y) vaccine should<br />

complete an immunisation course with conjugate quadrivalent (ACW 135<br />

Y) vaccine. Those who received <strong>the</strong><br />

conjugate quadrivalent (ACW 135<br />

Y) vaccine more than 12 months previously should be given a second dose.<br />

7.6.5. Contacts <strong>of</strong> confirmed serogroup A, W 135<br />

or Y infections<br />

• Vaccination with conjugate quadrivalent (ACW 135<br />

Y) vaccine should be <strong>of</strong>fered to all close contacts <strong>of</strong> any age<br />

(two doses, one month apart if aged between 2 – 12 months; one dose in older individuals).<br />

Recommendation<br />

• Depending on <strong>the</strong> serogroup <strong>of</strong> <strong>the</strong> index case, vaccination with MenC or MenACWY vaccine may be<br />

recommended <strong>for</strong> close contacts<br />

7.7 Vaccine failures<br />

Vaccine failure implies an inadequate response to <strong>the</strong> vaccine <strong>and</strong> may reflect host factors or sub-optimal storage<br />

or administration <strong>of</strong> <strong>the</strong> vaccine. All vaccine failures should be reported to HPSC as part <strong>of</strong> <strong>the</strong> ongoing monitoring<br />

<strong>of</strong> <strong>the</strong> Men C programme. Additionally a sample <strong>of</strong> convalescent serum prior to re-immunisation should be taken<br />

<strong>and</strong> sent to <strong>the</strong> IMMRL who will <strong>for</strong>ward <strong>the</strong> sample to <strong>the</strong> HPA Meningococcal Reference Unit <strong>for</strong> fur<strong>the</strong>r analysis.<br />

The IMMRL contact <strong>the</strong> clinician directly to arrange <strong>the</strong> sample.<br />

-66-

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!